Jacobus Recalls 3 Lots of Ruzurgi Due to Contamination

Jacobus Recalls 3 Lots of Ruzurgi Due to Contamination

306692

Jacobus Recalls 3 Lots of Ruzurgi Due to Contamination

Jacobus Pharmaceutical has issued a voluntary recall for three lots of Ruzurgi (amifampridine), a medication that is approved in the U.S. to treat people with Lambert-Eaton myasthenic syndrome (LEMS) ages 6–17. According to the company’s announcement, while doing confirmatory full testing on one of the lots, control number 18038, Jacobus’ Canadian partner found that the medication was contaminated with yeast, mold, and aerobic bacteria. These microorganisms can cause serious and life-threatening infections if ingested. This…

You must be logged in to read/download the full post.